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Background: B. bronchiseptica infections are usually associated with wild or domesticated animals, but infrequently
with humans. A recent phylogenetic analysis distinguished two distinct B. bronchiseptica subpopulations, designated
complexes I and IV. Complex IV isolates appear to have a bias for infecting humans; however, little is known
regarding their epidemiology, virulence properties, or comparative genomics.
Results: Here we report a characterization of the virulence of human-associated complex IV B. bronchiseptica strains.
In in vitro cytotoxicity assays, complex IV strains showed increased cytotoxicity in comparison to a panel of complex
I strains. Some complex IV isolates were remarkably cytotoxic, resulting in LDH release levels in A549 cells that were
10- to 20-fold greater than complex I strains. In vivo, a subset of complex IV strains was found to be hypervirulent,
with an increased ability to cause lethal pulmonary infections in mice. Hypercytotoxicity in vitro and hypervirulence
in vivo were both dependent on the activity of the bsc T3SS and the BteA effector. To clarify differences between
lineages, representative complex IV isolates were sequenced and their genomes were compared to complex I
isolates. Although our analysis showed there were no genomic sequences that can be considered unique to
complex IV strains, there were several loci that were predominantly found in complex IV isolates.
Conclusion: Our observations reveal a T3SS-dependent hypervirulence phenotype in human-associated complex IV
isolates, highlighting the need for further studies on the epidemiology and evolutionary dynamics of this B.
bronchiseptica lineage.
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Human pathogens often evolve from animal reservoirs,
and changes in virulence sometimes accompany acquisi-
tion of the ability to infect humans [1]. Examples include
smallpox virus, HIV, enterohemorrhagic E. coli, and Bor-
detella pertussis. Understanding how these events occur
requires the ability to reconstruct evolutionary history,
and this can be facilitated by the identification of evolu-
tionary intermediates. An experimentally tractable op-
portunity to study human adaptation is provided by
Bordetella species. The Bordetella genus currently* Correspondence: jfmiller@ucla.edu
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colonize respiratory epithelial surfaces in mammals.
B. pertussis, the etiological agent of pertussis (whooping
cough) is exclusively adapted to humans; B. parapertus-
sis refers to two groups, one infects only humans and
the other infects sheep [2,3]; and B. bronchiseptica estab-
lishes both asymptomatic and symptomatic infections in
a broad range of mammalian hosts, which sometimes in-
clude humans [4-7]. Numerous studies have implicated
B. bronchiseptica as the closest common ancestor of
human-adapted bordetellae, with B. pertussis and
B. parapertussishu, evolving independently from different
B. bronchiseptica lineages [8-10]. The genomes of these
3 species differ considerably in size and B. pertussis andtd. This is an Open Access article distributed under the terms of the Creative
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ably as a consequence of niche restriction [6].
Most mammalian bordetellae express a common set of
virulence factors which include putative adhesins such
as filamentous hemagglutinin (FHA), fimbriae, and per-
tactin, and toxins such as a bifunctional adenylate
cyclase/hemolysin, dermonecrotic toxin, and tracheal
cytotoxin. B. pertussis additionally produces pertussis
toxin [7]. Of particular significance here is the bsc type
III secretion system (T3SS) locus which encodes compo-
nents of the secretion machinery, associated chaperones,
and regulatory factors. Remarkably, only a single T3SS
effector, BteA, has been identified to date [11-13]. BteA
is an unusually potent cytotoxin capable of inducing
rapid, nonapoptotic death in a diverse array of cell types
[14-16]. T3SS and bteAloci are highly conserved in B.
pertussis, B. parapertussis, and B. bronchiseptica [14,15].
A seminal phylogenetic analysis using multilocus se-
quence typing (MLST) of 132 Bordetella stains with di-
verse host associations led to the description of a new B.
bronchiseptica lineage, designated complex IV, which dif-
fers in several respects from the canonical complex I
B. bronchiseptica cluster [10]. Complex I strains are most
commonly isolated from non-human mammalian hosts,
whereas the majority of complex IV strains were from
humans, many with pertussis-like symptoms. Complex IV
strains were found to exclusively share IS1663 with B. per-
tussis, suggesting a close evolutionary relationship among
these lineages. Complex IV strains and B. pertussis are
proposed to share a common ancestor, although the genes
encoding pertussis toxin (ptxA-E) and the ptl transport
locus were found to be missing in the majority of complex
IV strains that were sampled [10]. Additionally, several
other B. pertussis virulence genes were also found to be
absent or highly divergent, including those encoding der-
monecrotic toxin, tracheal colonization factor, pertactin,
and the lipopolysaccharide biosynthesis locus. Differences
between virulence determinants expressed by B. pertussis
and complex IV strains have been suggested to be driven
by immune competition in human hosts [10], a model also
proposed for differences observed between B. pertussis
and B. parapertussishu [17].
Given their apparent predilection of complex IV B.
bronchiseptica isolates for human infectivity, we have
initiated a systematic analysis of their virulence proper-
ties and mechanisms. We found that complex IV strains,
on average, display significantly elevated levels of cyto-
toxicity in comparison to complex I isolates. Several
complex IV strains are also hyperlethal in mice, and
hyperlethality in vivo as well as cytotoxicity in vitro is
dependent on the BteA T3SS effector protein [11,12].
Comparative whole-genome sequence analysis of four
complex IV isolates was used to identify similarities and
differences between B. bronchiseptica lineages. Resultsfrom genome comparisons did not identify significant
genomic regions that are unique to complex IV strains
but missing from complex I isolates. This implies that
complex IV-specific phenotypes are determined by poly-
morphisms in conserved genes, differential regulation
[18], or other epigenetic mechanisms rather than acqui-
sition or retention of unique genomic determinants.
Methods
Bacterial strains and growth conditions
Strains and plasmids used in this study are listed in
Table 1. Bacteria were grown in Stainer-Scholte liquid
(SS) medium at 37°C [19] or on Bordet–Gengou (BG)
agar (Becton Dickinson Microbiology systems) supple-
mented with defibrinated sheep blood at a concentration
of 7.5% and incubated at 37°C. RB50 [20] was grown
from archived, low passage, frozen glycerol stock. Anti-
biotics were added to the following final concentrations:
ampicillin (Ap), 100 μg/ml; chloramphenicol (Cm),
25 μg/ml; Streptomycin (Sm), 20 μg/ml; Kanamycin
(km), 50 μg/ml; Gentamycin (Gm), 20 μg/ml.
Sample preparation, protein electrophoresis and
immunoblotting
For SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
sample preparation, bacteria were cultured in SS media
overnight and harvested by centrifugation at 10,000 x g
at 4°C for 10 min. The resulting supernatant, containing
secreted proteins, was filtered through a 0.2-μm mem-
brane to remove contaminating bacterial cells. Protein
from supernatants (equivalent of 3.75 O.D.600) was pre-
cipitated with 15% trichloroacetic acid (TCA) for 1 h on
ice and samples were centrifuged at 15,000 g for 15 min
at 4°C. After centrifugation, TCA was removed and the
pellet was resuspended in 1 X SDS-loading dye with
25 mM freshly prepared DTT. To neutralize the acidic
pH of the samples, a few crystals of tris-base were
added. Protein pellets were dissolved by shaking over a
bench-top shaker for 30 min at room temperature prior
to fractionation by various fixed percentage or gradient
(as indicated) pre-cast SDS-polyacrylamide gels (Bio-
Rad). The pellet samples after normalization to 12.5 O.
D.600/ml, were boiled for 10 min in 1 x SDS-loading dye
as above. After the run, proteins were either Coomassie
stained or transferred onto a polyvinylidene difluoride
(PVDF) membrane (Immobilon P, Millipore) using a
semi-dry blot. BvgS, a non-secreted protein control was
detected using polyclonal mouse antiserum at a dilution
of 1:1000 [21]. Pertactin (PRN), which is secreted by a
non-T3SS dependent pathway, was identified using a
monoclonal mouse antibody at a dilution of 1:1000 [22].
Bsp22, a T3SS substrate control, was detected using
polyclonal mouse serum at a dilution of 1:10,000 [23].
Immunodetection was carried out by chemifluorescence
Table 1 Bacterial strains, mammalian cells and plasmids used in this study
Bacterial strains or plasmids Alternate name Source Genotype or relevant characteristics Reference
E.coli strains
DH5α SupE44ΔlacU169 (Φ80lacZΔM15)
hsdR17recA1 endA1 gyrA96 thi-1 relA1
[48]
SM10λpir Expression of the π protein for
replication of suicide vector
[49]
Bordetella strains
RB50 Rabbit Complex-I strain, ST-12,Smr [20]
RB50ΔbscN WD3 RB50ΔbscN, Smr [15]
RB50ΔbteA RB50ΔbteA, Smr [11]
A309 SBL-F6116 Human Complex-IV strain, ST-9, Smr [10]
A310 SBL-F6368 Human Complex-IV strain, ST-8, Smr [10]
A345 GA96-01 Human Complex-IV strain, ST-21, Smr [10]
Bbr69 591 Dog Complex-IV strain, ST-22, Smr [10]
Bbr77 675 Human Complex-IV strain, ST-18, Smr [10]
D444 MO149 Human Complex-IV strain, ST-15, Smr [10]
D445 MO211 Human Human complex-IV strain, ST-17, Smr [10]
D446 MO275 Human Complex-IV strain, ST-3, Smr [10]
D758 00-P-2730 Human Complex-IV strain, ST-34, Smr [10]
D445ΔbscN Complex-IV strain, ST-17, Smr This study
D445ΔbteA Complex-IV strain, ST-17, Smr This study
Bbr77ΔbscN Complex-IV strain, ST-18, Smr This study
Bbr77ΔbteA Complex-IV strain, ST-18, Smr This study
Bbr68 590 Dog Complex-I strain, ST-10, Smr [10]
Bbr78 680 Koala bear Complex-I strain, ST-7, Smr [10]
Bbr79 401 Dog Complex-I strain, ST-7, Smr [10]
545 Pig Complex-I strain, ST-7, Smr [10]
548 Pig Complex-I strain, ST-4, Smr [10]
599 Dog Complex-I strain, ST-27, Smr [10]
601 Dog Complex-I strain, ST-4, Smr [10]
705 Rabbit Complex-I strain, ST-10, Smr [10]
723 Cat Complex-I strain, ST-23, Smr [10]
782 Cat Complex-I strain, ST-5, Smr [10]
BBE001 Human Complex I, ST-11 [34]
BBF579 Human Complex IV, Novel ST [34]
Mammalian cells
HeLa/CCL-2TM Human cervical adenocarcinoma cell line ATCC
A549/CCL-185TM Human lung carcinoma cell line ATCC
J774A.1/ TIB-67TM Mouse monocyte-macrophage cell line ATCC
Plasmids
pEGBR1005 pSS1129 based suicide plasmid harboring
bscN in-frame deletion of codons 171–261,
pir dependent, oriT, oriV, sacB, KmR
[15]
pRE112-ΔbteA pGP704 based suicide plasmid harboring bteA
in-frame deletion of codons 4–653, pir
dependent, oriT, oriV, sacB, CmR
[11]
pBBR1MCS-5 lacPOZ’ mob+, broad-host- cloning vector, GmR [50]
pbteA bteA cloned into pBBR1MCS-5, GmR [11]
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IgG and the ECL plusW detection substrate (GE Health-
care). Chemifluorescent signals were visualized using a
Typhoon scanner (GE Healthcare).
Genomic DNA extraction, PCR-based detection and
genome sequencing
DNA was extracted from overnight cultures of various
isolates using the PureLink genomic DNA kit as per
manufacturer’s instructions (Invitrogen Corporation,
USA). PCR was performed according to the manu-
facturer's instructions (0.5 U of iproof polymerase,
200 μM each of the four dNTPs and 1 μM each pri-
mer) and supplemented with 3% dimethyl sulphoxide
(DMSO). Primers B77_QseC1F (50- ATGACTTTGCAG
CGCAGGTT −30) and B77_QseC1R (50- AGAAACG
CGATCAGCACGGG −30) or primers B77_QseC2F
(50- GGAGATCTTGCCGTCGCCAT-30) and B77_QseC2R
(50-ACTTCCCATTGCGCGCGTAG-30) were used to
amplify qseC sequences, and primers B77_QseB1F (50-
GAGAATTCTTATTGTCGAAG-30) and B77_QseB1R
(50- GATTCCCAGTCATACAGCTT −30) were used to
amplify qseB. Cycling parameters were: one cycle of
98°C for 1 min; 25 cycles of 98°C for 10 s, 55°C for
20 s and 72°C for 30 s; and a final incubation at 72°C
for 5 min. The PCR products were fractionated on 1%
agarose gel using 1X TBE buffer containing 5 μg/ml
ethidium bromide. PCR products of the extracted DNA
were then purified for sequencing using Qiagen's QIA-
quick purification kit (Qiagen, Valencia, USA). Bordetella
genomes were sequenced by the Sequencing Group at
the Sanger Center and can be obtained from ftp://ftp.
sanger. ac.uk/pub/pathogens/bp.
Construction of bscN and bteA in-frame deletion mutants
To construct in-frame deletions of codons 171–261 in
the bscN locus, allelic exchange was performed using
pEGBR1005 suicide plasmid derivatives as previously
described by Yuk et al. [15]. For construction of bteA in-
frame deletions (codons 4–653), suicide plasmid
pRE112-bteA was used as previously described by Panina
et al. [11]. All mutants were verified by sequencing tar-
get open reading frames.
Cell lines
Cell lines used in this study were obtained from the Ameri-
can Tissue Culture Collection (ATCC). Human Cervical
Adenocarcinoma, HeLa (ATCC CCL-2TM) and Mouse
Monocyte-macrophage, J774A.1 (ATCC TIB-67TM) cell
lines were maintained in Dulbecco's Modified Eagle
Medium(DMEM), and Human Lung Carcinoma, A-549
cells (ATCC CCL-185TM) were maintained in Ham’s F-12 K
medium (F-12 K) supplemented with 10% Fetal bovine
serum (FBS) at 37°C with 5% CO2.Cytotoxicity assays
Bacteria were cultured in SS media overnight and were
then sub-cultured in SS media to an optical density
of ~0.5 at 600 nm. For cytotoxicity assays, bacteria
were added to previously seeded cell monolayers in 12-
or 24-well tissue culture plates at the indicated MOIs.
The plates were centrifuged for 5 min at 60 x g and
incubated for up to 4 h at 37°C with 5% CO2. To meas-
ure cell cytotoxicity, Lactate dehydrogenase (LDH) re-
lease was used as a surrogate marker for cell death. LDH
release in the supernatant media was assayed using a
CytoTox 96W non-radioactive cytotoxicity assay kit (Pro-
mega, Madison, WI), according to the manufacturer's
instructions. The maximal LDH release was defined as
100% and was determined by adding lysis solution to un-
infected monolayers, determining the absorbance at
490 nm, and then subtracting the background value.
Each sample was measured in triplicate in at least three
independent experiments.
Animal infection experiments
Wild-type female C57BL/6NCr (B6) mice, 4–6 weeks of
age, were purchased from Charles River Breeding La-
boratories (Wilmington, MA). The animals were lightly
sedated with isoflurane (Novation Laboratories, TX)
prior to intranasal infection with the indicated number
of CFU of bacteria in a total volume of 40 μl of
phosphate-buffered saline (PBS, Mediatech Inc, VA).
Bacteria were cultured in SS media overnight and were
then sub-cultured in SS media to an optical density of
~0.5 at 600 nm. Inocula were confirmed by plating serial
dilutions. For survival curves, groups of four mice were
inoculated with the indicated dose, and the percent sur-
vival was monitored over a 30-day period. Mice with le-
thal bordetellosis, indicated by ruffled fur, labored
breathing, and diminished responsiveness, were eutha-
nized to alleviate unnecessary suffering [24]. To enumer-
ate the number of bacteria in respiratory organs, groups
of three to four mice were sacrificed at the indicated
time points and bacterial numbers in the lungs and tra-
cheas were quantified by plating dilutions of tissue
homogenates on BG plates with appropriate antibiotics,
following incubation at 37°C for 2 days. The mean ± the
standard error was determined for each group. The stat-
istical significance between different groups was calcu-
lated by Student's two-tailed t-test. A significance level
was set at P values of ≤0.05. All animal experiments
were repeated at least three times with similar results.
Murine survival percentage was analyzed with the Log-
Rank (Mantel-Cox) test. All mice were maintained in
UCLA animal research facilities according to National
Institutes of Health and University of California Institu-
tional Animal Care Committee guidelines. Animals were
housed under specific pathogen-free conditions with free
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by the UCLA Chancellor's Animal Research Committee.
Histopathological analysis
Lungs were inflated with 10% neutral buffered formalin
at the time of necropsy. Following fixation, tissue sam-
ples were embedded in paraffin, sectioned at 5 μm, and
stained with hematoxylin-eosin, Giemsa, and Warthin-
Starry for light microscopic examination at the Transla-
tional Pathology Core Laboratory of UCLA. Sections
were scored for pathology by a veterinarian with training
and experience in rodent pathology who was blinded to
experimental treatment. The degree of inflammation was
assigned an arbitrary score of 0 (normal = no inflamma-
tion), 1 (minimal = perivascular, peribronchial, or patchy
interstitial inflammation involving less than 10% of lung
volume), 2 (mild = perivascular, peribronchial, or patchy
interstitial inflammation involving 10-20% of lung vol-
ume), 3 (moderate = perivascular, peribronchial, patchy
interstitial, or diffuse inflammation involving 20-50% of
lung volume), and 4 (severe = diffuse inflammation in-
volving more than 50% of lung volume).
In vitro adherence assays
Human lung epithelial (A549) cells and Human cervical
epithelial (HeLa) cells were grown in F-12 K and DMEM
medium, containing 10% fetal calf serum on cover slips
in standard 12-well tissue culture plates, respectively.
Bacteria in their mid-log phase were added to cell
monolayers at a MOI of 200 as previously described
[25]. The plates were spun at 200 × g for 5 min and then
incubated for 15 min at 37°C. The cells were then
washed six times with Hanks' balanced salts solution,
fixed with methanol, stained with Giemsa stain (Poly-
science, Warrington, PA) and visualized by light micros-
copy. Adherence was quantified by counting the total
number of bacteria per eukaryotic cell in at least three
microscopic fields from two separate experiments.
Trypsin digestion of polypeptides for mass spectrometry
For secretome analysis by mass spectrometry, bacteria
were cultured in SS media overnight and were then sub-
cultured in SS media to an optical density at 600 nm of
~1.0. A 5 ml aliquot was removed and centrifuged at
10,000 x g at 4°C for 10 min to remove bacterial cells.
The resulting supernatant, containing proteins secreted
into the culture medium, was filtered through a 0.2 μm
membrane to remove contaminating bacterial cells. The
filtered supernatants were then desalted and con-
centrated using a centrifugal filter device (Amicon Ultra-
3 K, Millipore) into ~300 μl of 50 mM ammonium
bicarbonate buffer. The samples were reduced by incu-
bation in 10 mM dithiotreitol (DTT) in 50 mM ammo-
nium bicarbonate at 37°C for 1 h. They were thenalkylated by adding 55 mM iodoacetamide in 50 mM
ammonium bicarbonate and incubated at 37°C in dark
for 1 h. Finally, the samples were digested at 37°C over-
night with addition of 75 ng trypsin (EC 3.4.21.4, Pro-
mega) in 50 mM ammonium bicarbonate. For in-gel
trypsin digestion of polypeptides, a previously described
method was used [26].
Nano-liquid chromatography with tandem mass
spectrometry (nLC-MSMS)
nLC-MS/MS with Collision Induced Dissociation (CID)
was performed on a linear trap quadrupole fourier trans-
form (LTQ FT, Thermo Fisher, Waltham, MA) integrated
with an Eksigent nano-LC. A prepacked reverse-phase
column (Microtech Scientific C18 with a dimension of
100 μm x 3.5 cm) containing resin (Biobasic C18, 5-μm
particle size, 300-Å pore size, Microtech Scientific,
Fontana, CA) was used for peptide chromatography and
subsequent CID analyses. ESI conditions using the
nano-spray source (Thermo Fisher) for the LTQ-FT
were set as follows: capillary temperature of 220°C, tube
lens 110 V, and a spray voltage of 2.5 kV. The flow rate
for reverse-phase chromatography was 5 μl/min for
loading and 300 nl/min for the analytical separation
(buffer A: 0.1% formic acid, 1% acetonitrile; buffer B:
0.1% formic acid, 100% acetonitrile). Peptides were
resolved by the following gradient: 2–60% buffer B over
40 min, then increased to 80% buffer B over 10 min and
then returned to 0% buffer B for equilibration of
10 min. The LTQ FT was operated in data-dependent
mode with a full precursor scan at high-resolution
(100000 at m/z 400) and six MSMS experiments at low
resolution on the linear trap while the full scan was
completed. For CID the intensity threshold was set to
5000, where mass range was 350–2000. Spectra were
searched using Mascot software (Matrix Science, UK) in
which results with p < 0.05 (95% confidence interval)
were considered significant and indicating identity. The
data was also analyzed through Sequest database search
algorithm implemented in Discoverer software (Thermo
Fisher, Waltham, MA).
Identification of the core, non-core, and pan-genome of
Bordetella
"Core" regions were defined as genome sequences that
were present in all 11 Bordetella genomes, while "non-
core" regions were defined as genome sequences that are
not present in all genomes. RB50 was used as the refer-
ence genome. For each of the other 10 sequences, gen-
omes were mapped to the reference genome using
Nucmer [27]. All 10 “.coords” output files from the Nuc-
mer program were analyzed to identify overlap regions
based on RB50 coordinates using a Perl script. Finally,
“core” sequences were extracted based on the genome
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Unshared regions were then added to the reference gen-
ome to make a “revised” reference genome, which con-
tained the original sequence plus unshared sequences.
This process was repeated until all of the genomes were
compared to include all unshared sequences included in
the pan-genome. The core region was subtracted from
the pan-genome of all the 11 genomes, and the
remaining regions were identified as non-core regions.
Hierarchical clustering using Cluster and Java Tree View
844 non-core fragments with more than 1000 bp were
identified. An 844 row x 11 column matrix, in which
1 means "present" while 0 means "absent" for each
non-core region, was entered to the Cluster program
(http://bonsai.hgc.jp/~mdehoon/software/cluster/software.
htm#ctv) [28]. Average linkage was used for clustering.
The Java Tree View program [28] was used to show the
clustering result.
Results
Hypercytotoxicity of complex IV isolates in vitro
Cytotoxicity against a broad range of cell types is a
hallmark of B. bronchiseptica infection in vitro
[11,12,14,16,23]. To measure relative levels of cytotox-
icity, human epithelial cells (HeLa), murine monocyte-
macrophage derived cells (J774A.1), or human
pneumocyte-derived cells (A549) were infected with an
array of complex I or complex IV B. bronchiseptica iso-
lates (Figure 1A-C). These strains represent different
multilocus sequence types (STs), and they were isolated
from both human and non-human hosts (Table 1). Lac-
tate dehydrogenase (LDH) release was used as a surro-
gate marker for cell death, and RB50, an extensively
characterized complex I rabbit isolate classified as ST12,
was used as a positive control for cytotoxicity [20]. An
isogenic RB50 derivative with a deletion in bscN, which
encodes the ATPase required for T3SS activity [15],
served as a negative control.
For HeLa (Figure 1A) and J774A.1 cells (Figure 1B),
single time point assays showed a distinct trend, in
which complex IV strains displayed higher levels of cyto-
toxicity than complex I isolates. For A549 cells the
results were more dramatic (Figure 1C). Unlike other
cell types previously examined [11,16,29], A549 cells are
nearly resistant to cell death mediated by the RB50 T3SS
(see RB50 vs. RB50ΔbscN; Figure 1C). Similarly, other
complex I strains displayed little or no cytotoxicity
against these cells. In striking contrast, incubation with
complex IV isolates resulted in significant levels of cell
death (p < 0.0001; Figure 1C). For A549 cells, strains
D444 (ST15), D445 (ST17), D446 (ST3) and Bbr77
(ST18) were 10- to 15-fold more cytotoxic than RB50.
Parallel assays measuring bacterial attachment to A549cells did not detect significant differences between com-
plex I and complex IV isolates, indicating that relative
levels of adherence are not responsible for the observed
differences in cytotoxicity (Additional file 1: Table S1).
Kinetic studies were performed next to increase the
resolution of the analysis. We examined relative levels of
cytotoxicity conferred by five complex IV strains towards
HeLa, J774A.1 or A549 cells as a function of time, using
RB50 as a complex I representative strain and
RB50ΔbscN as a negative control. Following infection at
an MOI of 50, cultures were sampled over a 4 h time
period for measurements of LDH release. Using HeLa
cells, which are exceptionally sensitive to T3SS-mediated
killing, only minor differences were detected between
strains (Figure 2A). Although two of the complex IV
strains, Bbr77 and D444, displayed slightly elevated cyto-
toxicity at intermediate time points, all strains reached
maximum lysis by the end of the 4 h time course. For
J774 cells, differences between complex IV strains and
RB50 were apparent throughout the experiment, with
Bbr77 and D444 showing the highest levels of activity
(Figure 2B). As expected, the most dramatic differences
were seen with A549 cells (Figure 2C). Most complex IV
strains displayed a marked hypercytotoxicity phenotype
compared to RB50, with the exception of Bbr69 which
had an intermediate phenotype. Interestingly, Bbr69 is a
dog isolate whereas all of the other complex IV strains
tested were cultured from human infections.
Roles of the bsc T3SS and the BteA effector in
hypercytotoxicity by complex IV B. bronchiseptica isolates
To examine the hypercytotoxicity phenotype in detail,
two representative highly toxic complex IV strains of
human origin, D445 (ST17) and Bbr77 (ST18), were
chosen for further analysis. To measure the contribution
of the bsc T3SS, nonpolar in-frame deletions were intro-
duced into the bscN loci of D445 and Bbr77. As shown
in Figure 3A, bscN mutations eliminated in vitro cyto-
toxicity against all three cell types, demonstrating an es-
sential role for type III secretion. We next examined the
involvement of the BteA effector in hypercytotoxicity.
Previous studies have shown that BteA is essential for
T3SS-mediated cell death induced by RB50, and it is suf-
ficient for cytotoxicity when expressed in mammalian
cells [11]. For both complex IV strains, bteA deletion
mutations had a similar effect as ΔbscN mutations and
abrogated cytotoxicity (Figure 3A).
The BteA proteins expressed by Bbr77 and D445 are
identical except for the absence of two amino acids at
the extreme carboxyl end of D445 BteA (Figure 3B). In
contrast, when compared to RB50 BteA, the complex IV
effectors from Bbr77 and D445 differ at 22 or 24 posi-
tions, respectively (Figure 3B). Interestingly, BteA
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Figure 1 Cytotoxicity of complex I and complex IV B. bronchiseptica isolates. A. HeLa, B. J774A.1, or C. A549 cells were infected with the
indicated strains at a multiplicity of infection (MOI) of 50 in 24-well plates for 3 h. Following infection, release of lactate dehydrogenase (LDH) into
culture medium was measured as described in Materials and Methods. Complex I and complex IV strains are designated by blue or red bars,
respectively. P values were calculated by an unpaired two-tailed Student's t test.
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homologs in B. bronchiseptica RB50 or B. pertussis
Tohama I. To determine whether BteA polymorphisms
are responsible for differences in cytotoxicity pheno-
types, bteA deletion derivatives of all three strains were
complemented with the RB50 bteA allele on a medium
copy vector (Figure 3A) [11]. In each case, complemen-
ted levels of cytotoxicity were similar to those of the
wild type isolate. Most importantly, complemented
ΔbteA derivatives of strains D445 and Bbr77 regained
cytotoxicity against A549 cells, whereas RB50 ΔbteA/
pbteA remained non-cytotoxic against this cell line.
Taken together, these results demonstrate that the bsc
T3SS and the BteA effector are essential for cytotoxicity
by D445 and Bbr77. The hypercytotoxicity phenotypes
of the complex IV isolates, however, are not due to poly-
morphisms in BteA. This is consistent with the con-
served nature of this effector, both within and between
Bordetella species [11]. Differential regulation of T3SS
activity, the presence of novel secretion substrates, or
alterations in accessory factors could account for pheno-
typic differences between strains (see Discussion).
T3SS secretome analysis
We next compared polypeptide profiles of proteins
secreted into culture supernatants by the isolates exam-
ined in Figure 3. Strains D445, Bbr77, and RB50 were
grown to early mid-log phase in liquid medium under
conditions permissive for type III secretion (Bvg +phase
conditions, see Methods) [15]. To specifically identify
T3SS substrates, ΔbscN derivatives were examined in par-
allel. Culture supernatants were TCA-precipitated,
digested with trypsin, and separated by reverse-phase
nano-liquid chromatography on a C18 column followed
by tandem mass spectrometry (nLC-MSMS). Peptide pro-
files were queried against the RB50 protein database.
Nearly identical sets of peptides were detected in superna-
tants from strains D445, Bbr77 and RB50, and these
included peptides corresponding to T3SS substrates previ-
ously identified using RB50 (Table 2). Bsp22, which poly-
merizes to form an elongated needle tip complex [30],
BopB and BopD, which form the plasma membrane trans-
location apparatus [14,29,31], BopN, a homolog of Yersi-
nia YscN which functions as a secreted regulator [32], and
the BteA effector were present in supernatants from wild
type strains, but absent in supernatants of ΔbscN deriva-
tives. In the course of this analysis we discovered a novel
T3SS substrate encoded from a conserved hypothetical
ORF (BB1639), herein named BtrA, in supernatant frac-
tions from RB50, D445 and Bbr77 but not from their
ΔbscN derivatives. Importantly, examination of complex
IV secretion substrates failed to identify unique polypep-
tides that were not expressed by RB50 or did not match
the RB50 protein database. The relative amounts of T3SSsubstrates released into culture supernatants, as assessed
by SDS-PAGE and western blot analysis, also failed to cor-
relate with relative levels of cytotoxicity (Additional file 2:
Figure S1). Although these observations did not reveal ob-
vious differences in the T3SS secretome that could ac-
count for the hypercytotoxic phenotypes of D445 and
Bbr77, it is important to consider that the activity of the
bsc T3SS and its substrate specificity are regulated at mul-
tiple levels, and results obtained using broth-grown cells
provide only a crude approximation of T3SS activity dur-
ing infection (see Discussion).
Virulence of complex IV strains during respiratory
infections
To determine if relative levels of cytotoxicity measured
in vitro correlate with virulence in vivo, we used a mur-
ine respiratory intranasal challenge model [24]. Groups
of 4–6 week old female specific-pathogen-free C57BL/
6NCr mice were intranasally infected with 5 x 105 CFU.
At this dose, RB50 establishes nonlethal respiratory
infections that generally peak around day 10 post-
inoculation and are gradually cleared from the lower re-
spiratory tract, while persisting in the nasal cavity [33].
As shown in Figure 4A, complex IV strains segregated
into two groups. The first caused lethal infections in
some (D444, Bbr77) or all (D445) of the infected ani-
mals. The second group (D446, Bbr69) caused nonlethal
infections similar to RB50.
In the experiment shown in Figure 4B, animals were
intranasally inoculated with 5 x 105 CFU of RB50 or the
two most virulent complex IV isolates, D445 and Bbr77,
and sacrificed three days later. Both complex IV isolates
were present in lungs at levels that were 10 to 30-fold
higher than RB50 (p < 0.001). Histopathological examin-
ation of lung tissue from mice infected with D445 or
Bbr77 showed severe and widespread inflammation,
affecting nearly the entire volume of the lung for D445
and up to 40% of the tissue for Bbr77 (Figure 4C & D).
Extensive migration of lymphocytes, macrophages, and
neutrophils resulted in severe consolidation of large
areas of lung parenchyma. Alveolar and interstitial
edema as well as extensive perivascular and peribronch-
iolar inflammation were also observed. In contrast, lungs
from animals infected with RB50 displayed only mild in-
flammation that covered less than 25% of the total lung
volume.
We also examined the relative roles of the bsc T3SS
and the BteA effector in the in vivo virulence phenotypes
of D445 and Bbr77. As shown in Figure 4A, deletions in
bscN or bteA abrogated lethality following infection by
either strain. Consistent with these observations, ΔbscN
and ΔbteA mutants also showed significantly decreased
numbers of bacteria in the lungs at day 3 post infection

























































































Figure 2 Time course cytotoxicity assays. A. HeLa, B. J774A.1, or C. A549 cells were infected with the indicated strains at a multiplicity of
infection (MOI) of 50 in 12-well plates. Aliquots of culture supernatants were removed at the indicated times and lactate dehydrogenase (LDH)
levels were measured as described in Materials and Methods. Complex I and complex IV strains are designated by blue or red lines, respectively.
Due to repeated sampling of culture medium for LDH release assays, we consistently observe a slight increase in cytotoxicity measured in kinetic
experiments vs. single time point assays as shown in Figure 1. The differences range from none to less than 20 %, depending on the cytotoxicity
of the isolate. Error bars represent standard errors for measurements from at least three independent experiments.
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http://www.biomedcentral.com/1471-2180/12/167histopathology (Figure 4C). These results demonstrate
that in comparison to the prototype complex I strain
RB50, D445 and Bbr77 are more virulent in mice follow-
ing respiratory infection, and hypervirulence is
dependent on type III secretion and BteA.
Comparative whole-genome analysis of complex I and
complex IV B. bronchiseptica strains
To determine if hypervirulent complex IV B. bronchisep-
tica strains share common genomic regions that might
be responsible for the phenotypes reported here, we
obtained whole genomic sequences of D444 (MO149),
Bbr77, and D445 using next-generation high throughput

































































































Bp Tohama I BteA 
Figure 3 Roles of the bsc T3SS and the BteA effector in cytotoxicity. A
infected with the indicated strains at a multiplicity of infection (MOI) of 50
in trans with the RB50 bteA allele carried on a medium copy vector (see M
into culture medium was measured as described in Methods. B. bteA homo
differences are shown. Green lines indicate substitutions of highly conserve
similarity, cyan dotted lines designate deletion of a residue and pink design
LRT = lipid raft-targeting domain [12].sequences of B. bronchiseptica strains BBE001 and 253
(complex I human isolates) [34,35], BBF559 (complex IV
human isolate) [34], and RB50 [20]; B. pertussis strains
Tohama I and 18323 [36]; and B. parapertussis strains
12822 and Bpp5 (human and ovine isolates, respectively)
[37,38]. The B. bronchiseptica sequences were in various
stages of assembly at the time of analysis (Table 3). Hier-
archical clustering of virtual comparative genomic
hybridization data supports previous MLST assignments
of phylogenic relationships between Bordetella strains
[10], as isolates from each complex are clustered to-
gether (Figure 5). Genome alignments reveal that these










































































































































































































































. HeLa (blue bars), J774A.1 (red bars), or A549 cells (green bars) were
in 24-well plates for 3 h. The bteA mutant strains were complemented
ethods). Following infection, release of lactate dehydrogenase (LDH)
logues were compared using multialign [51] and amino acid
d residues, blue shows weakly similar amino acids, red indicates no
ates an amino acid insertion. Bp = B. pertussis, Bpp= B. parapertussis,
Table 2 nLC-MSMS secretome analysis
Protein name NCBI accession number Sequence coverage (%)
RB50 RB50ΔbscN D445 D445ΔbscN Bbr77 Bbr77ΔbscN
Bsp22 gi|33568201 41 - 59 - 60 -
BopN gi|33568200 24 - 29 - 24 -
BopB gi|33568205 5 - 5 - 18 -
BopD gi|33568204 50 - 51 - 54 -
BteA gi|33568834 7 - 6 - 28 -
BtrA gi|33568223 26 - 18 - 26 -
Summary of nLC-MSMS data indicated as peptide coverage for indicted T3SS substrate proteins in supernatant fractions from B. bronchiseptica strains grown to
mid-log phase in Stainer-Scholte medium.
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non-core genome to identify potential loci shared only
by complex IV strains. Despite sequences that are shared
by more than one complex IV isolate, we did not iden-
tify complex IV genomic sequence(s) that uniquely dif-
ferentiate complex IV from complex I strains. Strains
D445, Bbr77 and D444 do, however, contain clusters of
shared genes that are not present in other Bordetella
genomes (Figure 5B, yellow boxes). Although these loci
are missing in BBF579, the virulence properties of this
isolate has not been reported, raising the possibility that
one or more of these loci may contribute to hyperviru-
lence by a subset of complex IV strains. Blastn analysis
of overlap regions revealed a diverse set of genes
involved mainly in signal transduction, metabolism,
adhesin/autotransporter expression and type IV secre-
tion of unknown substrates (Figure 5B).
One locus of potential interest, found in two out of
four sequenced complex IV isolates (Bbr77 and D444)
but none of the other Bordetella genomes, is predicted
to encode homologs of the QseBC two-component regu-
latory system found in numerous bacterial pathogens
[39]. In enterohemorrhagic E. coli (EHEC) and Salmon-
ella sp., QseBC has been shown to sense host stress hor-
mones (epinephrine and norepinephrine) and regulate
virulence gene expression [40-44]. The qseBC open read-
ing frames from Bbr77 and D444 are identical, and their
predicted products share 47% amino acid identity and
63% similarity with EHEC QseB, and 34% identity and
51% similarity with EHEC QseC, respectively. Using a
PCR-based assay, we screened for the presence of qseBC
in a larger collection of B. bronchiseptica isolates. As
shown in Figure 5C, this locus is present in 7 out of 9
complex IV isolates, but only 1 out of 10 complex I iso-
lates. Sequence analysis of PCR amplicons revealed high
levels of nucleotide identity (> 97%) between B. bronchi-
septicaqseBC alleles. Although highly enriched in com-
plex IV strains, qseBC is unlikely to represent a single,
conserved pathway for hypervirulence since it is absent
from strain D445. Nonetheless, the potential role ofQseBC in Bordetella-host interactions warrants further
study. In addition to examining gross genomic differ-
ences, we also analyzed polymorphisms in virulence loci.
Nearly all of the virulence genes shared a high degree of
homology (Additional file 3: Table S2). The bsc T3SS
locus, the btr genes involved in T3SS regulation, as well
as their upstream promoter regions had greater than
97% sequence conservation between RB50 and complex-
IV strains. Additionally, our analysis confirms the ab-
sence of ptx/ptl loci and divergence in tcfA and prn
genes in sequenced complex-IV isolates as previously
described by Diavatopoulos et al. [10].
Discussion
The existence of a distinct lineage of B. bronchiseptica
strains associated with human infections was described
several years ago [10]; however, little is known regarding
the virulence properties of complex IV isolates or their
epidemiological significance. Here we present evidence
that complex IV isolates display significantly higher
levels of cytotoxicity against a variety of cell lines
in vitro. For a subset of complex IV strains that were iso-
lated from humans with respiratory illness and represent
distinct sequence types, we also demonstrate that hyper-
cytotoxicity in vitro correlates with hypervirulence
in vivo, and that both phenotypes are dependent on the
bsc T3SS and the BteA effector.
To investigate the mechanistic basis for the quantita-
tive differences in BteA-dependent cytotoxicity observed
between complex I and complex IV strains, we took a
genetic approach which is both simple and definitive. In
the experiment in Figure 3A, we show that when the
RB50 bteA allele is expressed in ΔbteA derivatives of
RB50 or hypercytotoxic complex IV strains (D445 and
Bbr77), the cytotoxicity profile of the parental strain is
maintained. Thus, hypercytotoxicity is not due to differ-
ences in the specific activity of the bteA products. Add-
itionally, the examination of culture supernatants also
failed to detect differences in the T3SS secretome that














































































Figure 4 In vivo characterization of selected complex IV B. bronchiseptica strains. A. Survival of wild-type female C57BL/6NCr (B6) mice
inoculated with different strains of B. bronchiseptica. Groups of four mice were intranasally inoculated with 5 x 105 CFU of the indicated strains in
40 μl volumes as described in Methods. B. Female C57BL/6NCr (B6) mice were infected as above and sacrificed 3 days later. Lungs were removed,
homogenized in sterile PBS, and aliquots were plated on selective media. The number of colony forming units (CFU) per lung is shown for each
animal. C. Representative H&E-stained sections of lung tissue obtained on day 3 post infection with indicated strains (magnification, x5). D.
Histopathological score of indicated strains based on criterion described in Methods. The * indicates P value of <0.0001 for RB50 vs. Bbr77 and
RB50 vs. D445.
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cytotoxicity are expressed by complex IV strains at levels
that escape detection, it is also possible, and perhaps
even likely, that differences in regulation are at play. We
have previously shown that loci encoding bteA and bscT3SS apparatus components and chaperones are regu-
lated by the BvgAS phosphorelay through an alternative
ECF-sigma factor, BtrS [11,23]. In addition to transcrip-
tional control, the partner-switching proteins BtrU, BtrV
and BtrW regulate the secretion machinery through a
Table 3 B. bronchiseptica strains used for whole genome
comparisons
Strain Size (Mb) ST (complex) Contigs/Scaffold
RB50 5.4 12 (I) 1
253 5.3 27 (I) 4
D444 5.1 15 (IV) 1
D445 5.2 17 (IV) 11
Bbr77 5.2 8 (IV) 16
BBE001 5.1 11 (I) 175
BBF579 4.9 (+IS481) novel (IV) 319
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by serine phosphorylation and dephosphorylation
[23,45]. Comparative expression analysis shows that dif-
ferential expression of the BvgAS regulon correlates with
human-adaptation by B. pertussis and B. parapertussis
[18]. In a similar vein, it seems reasonable to suspect
that T3SS regulatory systems may be adapting to the
evolutionary pressures that are shaping B. bronchiseptica
lineages.
Although both cytotoxicity and virulence are known,
or likely, to be T3SS-dependent phenotypes in all strains
examined, the correlation between lethality in mice and
LDH release in vitro was not absolute. Strain D446 was
highly cytotoxic to all cell lines examined (Figure 1), yet
it was relatively avirulent following respiratory infection
(Figure 4A). This is not unexpected given the fact that
type III secretion is only one of many virulence determi-
nants required for pathogenesis [7], and B. bronchisep-
tica isolates are known to have diverse phenotypic
properties despite their high degree of genetic similarity.
A recent study by Buboltz et al.. [46] identified two com-
plex I isolates belonging to ST32 which also appeared to
have heightened virulence when compared to RB50. In
particular, the LD50 of these strains was 40- to 60-fold
lower than RB50 and based on transcriptome analyses,
hypervirulence was associated with upregulated expres-
sion of T3SS genes. The authors also observed a T3SS-
dependent increase in cytotoxicity towards cultured
J774A.1 macrophage cells. It will be important to deter-
mine whether complex IV isolates do indeed share com-
mon virulence properties, or if the observations reported
here represent heterogeneity distributed throughout B.
bronchiseptica lineages.
Numerous studies have demonstrated the ability of the
bsc T3SS to exert potent cytotoxicity against a remark-
ably broad range of mammalian cell types, regardless of
their species or tissue of origin [11,12,14,15]. This was
considered to be a defining feature of the B. bronchisep-
tica T3SS. A549 cells, derived from human alveolar epi-
thelial cells, are the first cell line to our knowledgeshown to be resistant to intoxication by RB50. The find-
ing that complex IV isolates kill these cells with high ef-
ficiency provides particularly compelling evidence for
their hypercytotoxicity.
To begin to address the comparative genomics of B.
bronchiseptica lineages, we analyzed the genome
sequences of 4 complex IV and 3 complex I strains. The
observation that homologs of the qseBC locus are
present in multiple complex IV strains was an intriguing
discovery, as these genes encode a catecholamine-
responsive virulence control system in E. coli and Sal-
monella [39-42]. Since the locus is missing in two com-
plex IV strains (A345, D445), one of which is also
hypervirulent (D445), qseB and qseC do not satisfy the
criteria for either complex IV-specific or hypervirulence-
associated genes. No loci were found to be uniquely
present in all complex IV isolates, and we also failed to
identify loci that are present in all members of the
hypervirulent subset of complex IV strains and are pre-
dicted to encode factors involved in virulence. It is prob-
able that there are multiple pathways to hypervirulence,
and that polymorphisms between conserved virulence
and regulatory genes play a role in this phenotype as
well as the apparent predilection of complex IV isolates
for human infectivity.
A particularly relevant question that remains to be
addressed involves the burden of human disease cur-
rently caused by B. bronchiseptica. Diagnostic methods
in common use that rely on PCR-based identification ef-
ficiently detect B. pertussis and B. parapertussis, but not
B. bronchiseptica [47]. It is therefore possible that B.
bronchiseptica respiratory infections are more common
than previously appreciated, and it is intriguing to
speculate that complex IV isolates may be responsible
for undiagnosed respiratory infections in humans.
Conclusions
This work provides an initial characterization of the viru-
lence properties of human-associated B. bronchiseptica. In
in vitro cytotoxicity assays using several mammalian cell
lines, wild type complex IV isolates showed significantly
increased cytotoxicity as compared to a panel of complex
I strains. Some complex IV isolates were remarkably cyto-
toxic, resulting in LDH release levels that were 10- to 20-
fold greater than the prototype complex I strain RB50.
While infection of C57/BL6 mice with RB50 resulted in
asymptomatic respiratory infection, a subset of complex
IV strains displayed hypervirulence which was character-
ized by rapidly progressive pneumonia with massive peri-
bronchiolitis, perivasculitis, and alveolitis. Although
in vitro cytotoxicity and in vivo hypervirulence are both
dependent upon T3SS activity and the BteA effector, the
exact mechanistic basis for quantitative differences in







































R01    6528    QseBC, heme oxygenase, Short chain dehydrogenase 
R03    1960    Autotransporter, Zn-dependent conserved protein 
R02    3156    Acyl-CoA dehydrogenase, Flavoprotein dehydrogenase 
R04    4040    Conserved hypothetical protein 
R06    4690    Thiamine pyrophosphate
R05    7321    Hydantoin utilization protein
R07    3517    L-carnitine dehydratase/bile acid-inducible protein F
R09    6045    CaiB/BaiF CoA-transferase family protein
R08    3899   TonB-dependent hemoglobin receptor
R10    6050    Short chain dehydrogenase 
R12    3683    Adhesin 
R11    1269    Hyothetical protein
R13    2481    Autotransporter-like protein
R15    1968    Conjugative transfer ATPase
R14    1090    Twin-arginine translocation pathway signal
R16    2364    DEAD-like helicase
R18    2089    SNF2 family helicase
R17    3411    Type III restriction protein res subunit 
R19    2000    extra-cytoplasmic solute receptor family protein
R21    2383    CobQ/CobB/MinD/ParA nucleotide binding domain-containing protein 
R20    7419    Acetolactate synthase large subunit, IclR family transcriptional regulator
R22    10813  DNA topoisomerase III, DNA methyltransferase
R24    6127    VirD4, type IV secretory pathway
R23    6270    GTPase SAR1 and related small G protein, ABC-type amino acid transport
R25    12034  TraG-like family protein, Hypothetical protein, Conjugative element protein
R27    1586    Adenine-specific DNA methyltransferas
R26    2862    RES domain protein, Relaxase
          Size (bp)                             Homology 





































































































Figure 5 Comparative genome analysis. A. Cluster analysis of non-core genome sequences of 11 Bordetella strains. The results are displayed
using TREEVIEW. Each row corresponds to a specific non-core region of the genome, and columns represent the analyzed strain. Yellow indicates
presence while blue represents absence of particular genomic segments. Abbreviations: Bp = B. pertussis, Bpph = human B. parapertussis, Bb
IV = complex IV B. bronchiseptica, Bb I = complex I B. bronchisetpica, Bppo = ovine B. parapertussis. B. Zoomed image of non-core region in panel A
marked with a red bracket showing complex IV specific regions. On the right, blastn with default settings was used to query the nucleotide
collection (nr/nt) from the National Center for Biotechnology Information and homology designations are indicated. C. Distribution of qseBC
alleles among complex I and complex IV B. bronchiseptica isolates based on PCR-based amplification and sequencing.
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http://www.biomedcentral.com/1471-2180/12/167B. bronchiseptica isolates is currently unresolved. A lim-
ited comparative genomic analysis did not reveal unique
genetic determinants that could potentially explain the
virulence phenotype associated with the complex IVisolates examined. Our observations of hypervirulence in
tissue culture and animal models of infection suggests that
further study of these potentially emerging human patho-
gens is warranted.
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Additional file 1: Table S1. Adherence of B. bronchiseptica isolates.
HeLa or A549 cells were infected at a multiplicity of infection (MOI) of
200 in 12-well plates for 15 min. After infection, cells were washed with
Hanks' balanced salts solution, fixed with methanol, stained with Giemsa
stain and visualized by light microscopy. Adherence was quantified by
counting the total number of bacteria per mammalian cell in at least
three microscopic fields from two separate experiments. ++, 100-200
bacteria/cell; +, 1-100 bacteria/cell, -, no attachment, nd, not determined.
Additional file 2: Figure S1. Secreted protein analysis of B.
bronchiseptica isolates. Cultures were grown to late-log phase and pellet
(0.125 OD600 equivalents) or supernatant (3.75 OD600 equivalents)
fractions were separated by SDS-PAGE and stained with Coomassie
brilliant blue. Molecular mass markers (kDa) are indicated on the left.
Labels on the right show the identities of proteins determined by mass
spectrometry.
Additional file 3: Table S2. tBLASTn comparisons of known virulence
genes. Values indicate % identity or % similarity at the amino acid level
with respect to RB50.
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